BioCentury on BioBusiness,
Intarcia rejects pharma term sheets; raises $210M to run diabetes Phase III
Related tables, figures and sidebars
Calling pharma's bluff
Monday, November 19, 2012
Not satisfied with partnership offers for ITCA 650, Intarcia
Therapeutics Inc. raised $210 million last week from investors who
bought into the potential of the company's once-yearly GLP-1 product. The money
will pay for a Phase III program in Type II diabetes and leave Intarcia better
positioned to revisit negotiations with prospective commercial partners in
In December, Intarcia took an important step toward moving
ITCA 650 into Phase III testing by finalizing a deal with Quintiles
Transnational Corp. in which the CRO became both a financial and a
development partner on the program (see BioCentury, Jan. 9).
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]